N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan for Patients With Relapsed or Refractory Neuroblastoma

Trial Profile

N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan for Patients With Relapsed or Refractory Neuroblastoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Eflornithine (Primary) ; Celecoxib; Cyclophosphamide; Topotecan
  • Indications Neuroblastoma
  • Focus Adverse reactions; Biomarker; Pharmacogenomic
  • Most Recent Events

    • 11 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Jan 2018.
    • 11 Aug 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Oct 2017.
    • 11 Aug 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top